Sector: MedicalSalix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 270 |
Technical : | 199 |
Performance : | 65 |
Overall: | 208 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 273 |
Technical : | 254 |
Performance : | 109 |
Overall: | 260 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 272 |
Technical : | 174 |
Performance : | 84 |
Overall: | 210 |
Number of Stocks: | 306 |
Headlines
- The Fortune Financial Coverage of New Alliance Bancshares Inc., Men's Wearhouse Inc., Microsoft Corp., Hercules Offshore Inc., News Corp. and Salix Pharmaceuticals Ltd
Nov 23, 2009 06:25 AM | HERO, MSFT, MW, NWS, SLXP
- Salix Pharmaceuticals, Ltd. Announces Pricing of a Public Offering of Common Stock
Nov 18, 2009 09:09 AM | JEF, SLXP
- Salix Pharmaceuticals Reports 3Q2009 Results
Nov 09, 2009 04:01 PM | SLXP
- Salix Pharmaceuticals to Host Analyst Day on November 18
Nov 04, 2009 07:02 AM | SLXP
- FDA Approves New Salix Product Exclusively in Catalent's Zydis(R) Fast Dissolve Technology
Nov 03, 2009 10:11 AM | SLXP
- Salix Pharmaceuticals Reviews American Association for the Study of Liver Diseases Annual Meeting
Nov 02, 2009 07:00 AM | SLXP
- Lupin Q2 net profit rises 39%
Oct 26, 2009 03:19 PM | SLXP
- Salix Pharmaceuticals Previews American College of Gastroenterology 2009 Annual Scientific Meeting
Oct 26, 2009 11:00 AM | SLXP
- Salix Pharmaceuticals Announces 3Q2009 Financial Results Conference Call and Webcast
Oct 26, 2009 07:00 AM | SLXP
- FDA Calendar Extreme Trades: 85 Single Digit Stocks
Oct 13, 2009 12:34 PM | ACCP, APOL, CLDA, CRI, CRL, CYTX
- Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to Rifaximin
Nov 03, 2009 10:55 AM | SLXP
- Salix Pharmaceuticals Reports 2Q2009 Results Updates Full Year Guidance
Aug 10, 2009 04:10 PM | SLXP
- StockPreacher.com Issues Trading Outlook for ViroPharma Inc.
Aug 04, 2009 06:51 AM | AZN, CBST, GSK, SLXP, VPHM
- Salix Pharmaceuticals to Present at BMO Conference
Jul 29, 2009 07:03 AM | SLXP
- Salix Pharmaceuticals Announces 2Q2009 Financial Results Conference Call and Webcast
Jul 27, 2009 07:02 AM | SLXP
- Salix’s Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission from Ulcerative Colitis
Jun 02, 2009 09:10 AM | SLXP
- Salix's Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission From Ulcerative Colitis
Jun 02, 2009 09:01 AM | SLXP
- Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Jun 01, 2009 07:01 AM | SLXP
- Certain Salix Officers and Directors Adopt 10b5-1 Trading Plans for Stock Options That Are Scheduled to Expire During 2010
May 11, 2009 10:37 AM | SLXP
- Salix Pharmaceuticals Reports 1Q2009 Results
May 05, 2009 04:11 PM | SLXP
- Form 4 SALIX PHARMACEUTICALS For: Nov 18 Filed by: DERBYSHIRE ADAM C (10K)
Nov 19, 2009 06:35 PM
- Form 4 SALIX PHARMACEUTICALS For: Nov 11 Filed by: DERBYSHIRE ADAM C (10K)
Nov 13, 2009 04:53 PM
- Form 4 DERBYSHIRE ADAM C For: Nov 04 (10K)
Nov 06, 2009 10:28 AM
- Form 4 SALIX PHARMACEUTICALS For: Oct 21 Filed by: DERBYSHIRE ADAM C (10K)
Oct 23, 2009 05:01 PM
- Form 4 DERBYSHIRE ADAM C For: Oct 14 (10K)
Oct 14, 2009 05:26 PM
- Form 4 DERBYSHIRE ADAM C For: Oct 07 (10K)
Oct 08, 2009 06:32 PM
- Form 4 DERBYSHIRE ADAM C For: Sep 30 (10K)
Oct 01, 2009 05:38 PM
- Form 4 DERBYSHIRE ADAM C For: Sep 23 (10K)
Sep 24, 2009 06:09 PM
- Form 4 DERBYSHIRE ADAM C For: Sep 16 (10K)
Sep 16, 2009 06:12 PM
- Form 4/A LOGAN CAROLYN J For: Sep 14 (10K)
Sep 15, 2009 08:20 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
SLXP
|
Compare to S&P
|
| YTD |
165.12 %
|
119.42 %
|
| 4 Weeks |
14.19 %
|
12.96 %
|
| 12 Weeks |
86.53 %
|
75.86 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 53.12 %
|
|
EPS Growth in Last Year: -36.36 %
|
|
Sales Growth in Last Quarter: 25.70 %
|
|
Sales Growth in Last Quarter: 53.15 %
|
|
